40+ Years and Still no HIV Vaccine: Has Patience Been a Virtue?

  • Post author:
  • Post category:

The development of an HIV vaccine has been marked by both long-standing and emerging challenges and opportunities. In this video, Sanchia Theron, Global Head, Medical Affairs, and Andy Fleming, Senior Account Development Manager, discuss major takeaways from our roundtable discussion at World Vaccine Congress Washington: 40+ Years and Still no HIV Vaccine: Has Patience Been a Virtue?

Continue Reading40+ Years and Still no HIV Vaccine: Has Patience Been a Virtue?

Global Vaccine Development

  • Post author:
  • Post category:

To achieve our vision of a world where advances in vaccines help all people live longer, healthier lives, we’ve honed our processes to respond to the urgency and complexity of vaccine trials, developed our global network of investigators and sites, and partnered with organizations across public, private, academic and government sectors.

Continue ReadingGlobal Vaccine Development

Participant Recruitment and Retention Can Require Agile Solutions

  • Post author:
  • Post category:

Participant recruitment and retention can be challenged by many factors such as a long follow-up period, lack of accessible sites and unclear expectations. Our team helps develop and implement agile solutions to overcome these difficulties, as described in this video for multiple studies including a global, multi-site oncology trial.

Continue ReadingParticipant Recruitment and Retention Can Require Agile Solutions

Following the Epidemiology in Infectious Disease Trials: A COVID-19 Case Study

  • Post author:
  • Post category:

With infectious disease outbreaks, expanding immunity from previous infection and vaccination efforts can change where the outbreak is occurring. In this video, Loice Magaria, Clinical Research Project Manager at FHI Clinical discusses strategies implemented to address changing epidemiology in a study investigating COVID-19 treatments.

Continue ReadingFollowing the Epidemiology in Infectious Disease Trials: A COVID-19 Case Study